Jasper Therapeutics announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical study of subcutaneous briquilimab for the treatment of CIndU. The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria or symptomatic dermographism. “We are excited to announce dosing of the first patient in the SPOTLIGHT study in patients with CIndU, our second clinical program evaluating briquilimab in a mast cell-mediated disease,” said Edwin Tucker, Chief Medical Officer of Jasper. “As with our BEACON study in CSU, we expect the SPOTLIGHT study to establish proof of concept for the depletion of mast cells by briquilimab in CIndU and help us to determine doses and dosing regimens for future registrational studies. We plan to provide enrollment updates as we progress through the study and anticipate reporting preliminary data in the second half of 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JSPR:
- Jasper Therapeutics initiated with an Outperform at TD Cowen
- Jasper Therapeutics presents Phase 1b/2a data on briquilimab
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
- Bad News for Jasper Therapeutics, Inc. Stock: This New Risk Has Been Added
- Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments